Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapeutic" to "") |
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Acute lymphocytic leukemia]]=== | ===[[Acute lymphocytic leukemia]]=== | ||
− | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https:// | + | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://pubmed.ncbi.nlm.nih.gov/24579885 PubMed] [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] |
==Also known as== | ==Also known as== |
Revision as of 02:11, 25 February 2020
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article
Also known as
- Code name: AMG 412
- Brand name: LymphoCide